FIELD: biotechnology.
SUBSTANCE: adeno-associated virus (hereinafter – AAV) containing capsid protein, a composition for the treatment of a muscle-related disease or disorder, a method for the delivery of a transgene to a muscle cell, a method for the treatment of a subject suffering from a muscle-related disorder or disease, an expression vector, a cell for the expression of AAV capsid protein, the use of AAV in the manufacture of a drug for the treatment of a muscle-related disorder or diseases; cDNA containing a nucleotide sequence encoding capsid protein, a method for targeting a transgene to a muscle cell, and a method for the production of an adeno-associated virus (AAV) are presented.
EFFECT: invention allows for the use of an adeno-associated virus (AAV) in gene therapy methods.
72 cl, 10 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NEW LIVER TARGETING ADENO-ASSOCIATED VIRAL VECTORS | 2019 |
|
RU2793735C2 |
| RECOMBINANT VIRAL PARTICLES WITH MODIFIED TROPISM AND WAYS OF THEIR USE FOR TARGETED INTRODUCTION OF GENETIC MATERIAL INTO HUMAN CELLS | 2018 |
|
RU2811426C2 |
| RECOMBINANT VIRAL VECTORS WITH MODIFIED TROPISM AND WAYS OF THEIR USE FOR TARGETED INTRODUCTION OF GENETIC MATERIAL INTO HUMAN CELLS | 2018 |
|
RU2809246C2 |
| COMPOSITION FOR RELIEVING OR TREATING PAIN | 2017 |
|
RU2725830C1 |
| GENE THERAPY OF HYPOPHOSPHATEMIC DISEASES ASSOCIATED WITH FIBROBLAST GROWTH FACTOR 23 | 2020 |
|
RU2815545C2 |
| GENOTHERAPY CONSTRUCTIONS FOR TREATMENT OF WILSON'S DISEASE | 2020 |
|
RU2807158C2 |
| TREATMENT OF COMPLEMENT-MEDIATED DISORDERS | 2017 |
|
RU2768982C2 |
| MODIFIED FACTOR IX, AS WELL AS COMPOSITIONS, METHODS AND OPTIONS FOR THE USE OF GENE TRANSFER INTO CELLS, ORGANS AND TISSUE | 2016 |
|
RU2811445C2 |
| METHODS AND COMPOSITIONS FOR TREATMENT OF HUNTINGTON'S CHOREA | 2017 |
|
RU2764587C2 |
| RECOVERED NUCLEIC ACID WHICH CODES FVIII-BDD-BASED FUSION PROTEIN AND HETEROLOGOUS SIGNAL PEPTIDE, AND USE THEREOF | 2022 |
|
RU2818229C2 |
